Prevention of Inflammatory Bowel Diseases in Persons at Risk The PIONIR (Preventing IBD Onset in Individuals at Risk) Trial
NCT05211518 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2026-03-27
Summary
The goal of this study is to explore in a cross over randomized controlled trial, the ability of the Tasty\&Healthy dietary intervention (NCT04239248) to alter the parameters associated with future risk of developing Chron's disease (CD) using First Degree Relatives of patients with Crohn's disease, including subjects identified in the Genetic Environmental Microbiome (GEM) Study as having a high-risk score. Specifically, the investigators aim to determine if the Tasty\&Healthy dietary intervention can decrease the overall GEM Risk Score (GRS) and/or to alter the individual biological parameters that contribute to this score. The investigators hypothesize that the Tasty\&Healthy dietary approach will alter the risk of CD as reflected by a decrease in the GRS.
Conditions
- Inflammatory Bowel Diseases
Interventions
- OTHER
-
Tasty&Healthy
exclude pro-inflammatory dietary components
- OTHER
-
Habitual diet
subjects will continue their habitual diet.
Sponsors & Collaborators
-
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
collaborator OTHER -
The Hospital for Sick Children
collaborator OTHER -
The Governors of the University of Alberta
collaborator UNKNOWN -
University of Manitoba
collaborator OTHER -
IWK Health Centre
collaborator OTHER -
University of British Columbia
collaborator OTHER -
University of Calgary
collaborator OTHER - collaborator OTHER
-
Beilinson Hospital, Petach Tikva,Israel
collaborator UNKNOWN -
Shaare Zedek Medical Center
lead OTHER
Principal Investigators
-
Dan Turner, Prof · Saare Zedek Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 6 Years
- Max Age
- 38 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-05-04
- Primary Completion
- 2026-01-15
- Completion
- 2026-01-15
Countries
- Israel
Study Locations
More Related Trials
-
Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)
NCT00360022 ·Status: TERMINATED ·Phase: NA
-
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT05928039 ·Status: RECRUITING ·Phase: PHASE4
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173 ·Status: RECRUITING ·Phase: NA
-
The Crohn's Disease Exclusion Diet With Partial Enteral Nutrition or Alone in Adult Patients With Crohn's Disease
NCT02231814 ·Status: COMPLETED ·Phase: NA
-
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
NCT04974099 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
"Tasty&Healthy" Dietary Approach for Crohn's Disease
NCT04239248 ·Status: COMPLETED ·Phase: NA
-
Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
NCT04131504 ·Status: COMPLETED
-
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
NCT04777656 ·Status: RECRUITING ·Phase: PHASE3
-
B0151005 Open-Label Extension Study
NCT01345318 ·Status: COMPLETED ·Phase: PHASE2
-
Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care
NCT05221281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The ImageKids Study: Developing the pMEDIC and the PICMI
NCT01881490 ·Status: COMPLETED ·Phase: NA
-
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
NCT02425111 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease
NCT04082559 ·Status: UNKNOWN ·Phase: NA
-
Stop Infliximab in Patients With Crohn's Disease
NCT00571337 ·Status: COMPLETED ·Phase: PHASE3
-
The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
NCT03952364 ·Status: UNKNOWN
-
Predicting IBD Treatment Outcomes With Gut Microbiome Analysis
NCT06453720 ·Status: RECRUITING
-
Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
NCT06655415 ·Status: RECRUITING
-
Decoding Personalized Nutritional, Microbiome and Host Patterns Impacting Clinical and Prognostic Features in Crohn's Disease
NCT04283864 ·Status: ACTIVE_NOT_RECRUITING
-
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
NCT02316678 ·Status: COMPLETED
-
Precise Infliximab Exposure and Pharmacodynamic Control
NCT05660746 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease
NCT01548014 ·Status: UNKNOWN ·Phase: PHASE3
-
Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice
NCT02322008 ·Status: COMPLETED
-
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
NCT02247258 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease
NCT00287170 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073 ·Status: RECRUITING ·Phase: PHASE3